Laboratory Corporation of Ameri – Consensus Indicates Potential 26.3% Upside

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Laboratory Corporation of Ameri found using ticker (LH) have now 13 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 350 and 215 with the average target price sitting at 310.08. Given that the stocks previous close was at 245.49 this now indicates there is a potential upside of 26.3%. The 50 day moving average now sits at 254.97 and the 200 moving average now moves to 277.02. The market capitalisation for the company is $22,003m. Find out more information at: https://www.labcorp.com

The potential market cap would be $27,792m based on the market concensus.

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women’s health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations. It offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search